Background: Despite numerous genome-wide association studies conducted in psoriasis and psoriatic arthritis, only a small fraction of the identified genes has been therapeutically targeted. Objective: We sought to identify and analyze potential therapeutic targets for psoriasis and psoriatic arthritis (PsA) using the priority index (Pi), a genetics-dependent drug target prioritization approach. Methods: Significant genetic variants from GWAS for psoriasis, PsA, and combined psoriatic disease were annotated and run through the Pi pipeline. Potential drug targets were identified based on genomic predictors, annotation predictors, pathway enrichment, and pathway crosstalk. Results: Several gene targets were identified for psoriasis and PsA that demonstrated biological associations to their respective diseases. Some are currently being explored as potential therapeutic targets (i.e. ICAM1, NF-kB, REV3L, ADRA1B for psoriasis; CCL11 for PsA); others have not yet been investigated (i.e. LNPEP, LCE3 for psoriasis; UBLCP1 for PsA). Additionally, many nodal points of potential intervention were identified as promising therapeutic targets. Of these, some are currently being studied such as TYK2 for psoriasis, and others have yet to be explored (i.e. PPP2CA, YAP1, PI3K, AKT, FOXO1, RELA, CSF2, IFNGR1, IFNGR2 for psoriasis; GNAQ, PLCB1, GNAI2 for PsA). Conclusion: Through Pi, we identified data-driven candidate therapeutic gene targets and pathways for psoriasis and PsA. Given the sparse PsA specific genetic studies and PsA specific drug targets, this analysis could prove to be particularly valuable in the pipeline for novel psoriatic therapies.
Background: Despite numerous genome-wide association studies conducted in psoriasis and psoriatic arthritis, only a small fraction of the identified genes has been therapeutically targeted. Objective: We sought to identify and analyze potential therapeutic targets for psoriasis and psoriatic arthritis (PsA) using the priority index (Pi), a genetics-dependent drug target prioritization approach. Methods: Significant genetic variants from GWAS for psoriasis, PsA, and combined psoriatic disease were annotated and run through the Pi pipeline. Potential drug targets were identified based on genomic predictors, annotation predictors, pathway enrichment, and pathway crosstalk. Results: Several gene targets were identified for psoriasis and PsA that demonstrated biological associations to their respective diseases. Some are currently being explored as potential therapeutic targets (i.e. ICAM1, NF-kB, REV3L, ADRA1B for psoriasis; CCL11 for PsA); others have not yet been investigated (i.e. LNPEP, LCE3 for psoriasis; UBLCP1 for PsA). Additionally, many nodal points of potential intervention were identified as promising therapeutic targets. Of these, some are currently being studied such as TYK2 for psoriasis, and others have yet to be explored (i.e. PPP2CA, YAP1, PI3K, AKT, FOXO1, RELA, CSF2, IFNGR1, IFNGR2 for psoriasis; GNAQ, PLCB1, GNAI2 for PsA). Conclusion: Through Pi, we identified data-driven candidate therapeutic gene targets and pathways for psoriasis and PsA. Given the sparse PsA specific genetic studies and PsA specific drug targets, this analysis could prove to be particularly valuable in the pipeline for novel psoriatic therapies.
Entities:
Keywords:
drug targets; genetics-based discovery; priority index; psoriasis; psoriatic arthritis
Authors: Aline L Bressan; Bruna L S Picciani; Luna Azulay-Abulafia; Anna K Fausto-Silva; Paula N Almeida; Karin S G Cunha; Eliane P Dias; Sueli Carneiro Journal: Int J Dermatol Date: 2018-01-10 Impact factor: 2.736
Authors: Franak M Batliwalla; Wentian Li; Christopher T Ritchlin; Xiangli Xiao; Max Brenner; Teresina Laragione; Tianmeng Shao; Robert Durham; Sunil Kemshetti; Edward Schwarz; Rodney Coe; Marlena Kern; Emily C Baechler; Timothy W Behrens; Peter K Gregersen; Pércio S Gulko Journal: Mol Med Date: 2005 Jan-Dec Impact factor: 6.354
Authors: P Szodoray; P Alex; C M Chappell-Woodward; T M Madland; N Knowlton; I Dozmorov; M Zeher; J N Jarvis; B Nakken; J G Brun; M Centola Journal: Rheumatology (Oxford) Date: 2006-08-27 Impact factor: 7.580
Authors: Jason Doles; Trudy G Oliver; Eleanor R Cameron; Gerald Hsu; Tyler Jacks; Graham C Walker; Michael T Hemann Journal: Proc Natl Acad Sci U S A Date: 2010-11-10 Impact factor: 11.205
Authors: Dominik Schenten; Sven Kracker; Gloria Esposito; Sonia Franco; Ulf Klein; Michael Murphy; Frederick W Alt; Klaus Rajewsky Journal: J Exp Med Date: 2009-02-09 Impact factor: 14.307
Authors: Mehreen Soomro; Michael Stadler; Nick Dand; James Bluett; Deepak Jadon; Farideh Jalali-Najafabadi; Michael Duckworth; Pauline Ho; Helena Marzo-Ortega; Philip S Helliwell; Anthony W Ryan; David Kane; Eleanor Korendowych; Michael A Simpson; Jonathan Packham; Ross McManus; Cem Gabay; Céline Lamacchia; Michael J Nissen; Matthew A Brown; Suzanne M M Verstappen; Tjeerd Van Staa; Jonathan N Barker; Catherine H Smith; Oliver FitzGerald; Neil McHugh; Richard B Warren; John Bowes; Anne Barton Journal: Arthritis Rheumatol Date: 2022-08-04 Impact factor: 15.483